The finding is disarmingly simple for a field accustomed to complexity: a low-dose vitamin D supplement, taken daily alongside standard chemotherapy, nearly doubled the rate of complete cancer disappearance in women with breast cancer. The study is small. The implications are not.
Researchers at the Botucatu School of Medicine at São Paulo State University published results in the peer-reviewed journal Nutrition and Cancer this week, presenting what may be one of the more accessible and affordable potential advances in breast cancer treatment in recent years — a finding that carries particular significance for patients in lower- and middle-income countries where expensive adjunct therapies remain out of reach.
What the Study Found
The study was conducted at São Paulo State University involving 80 women over the age of 45 who were preparing to begin treatment at the oncology outpatient clinic of the general and teaching hospital at FMB-UNESP. After six months of cancer treatment and supplementation, 43% of the women taking vitamin D saw their tumors disappear following chemotherapy, compared to 24% in the placebo group.
That gap — 43% versus 24% — represents the 79% improvement in complete response rates that has drawn international attention from oncologists since the study’s publication. To be precise about what that number means: it is not a survival rate increase of 79 percentage points. It describes a relative improvement in the likelihood of achieving what clinicians call a pathological complete response — meaning no detectable cancer remaining in the breast tissue after chemotherapy concludes. The distinction matters for interpretation, but it does not diminish the finding’s significance. Pathological complete response is considered one of the strongest predictors of long-term survival in breast cancer patients undergoing neoadjuvant treatment.
All participants underwent neoadjuvant chemotherapy, a treatment used to shrink tumors before surgery. This is a standard approach for women with locally advanced breast cancer — the goal being to reduce the tumor enough to make subsequent surgery more effective, or to avoid more extensive surgery altogether. Achieving a complete response at this stage dramatically improves what comes next.
The Dose That Makes the Finding Striking
What makes this study particularly noteworthy is not just the magnitude of the outcome difference but the modesty of the intervention that produced it.
Eduardo Carvalho-Pessoa, president of the São Paulo Regional Brazilian Society of Mastology and one of the authors of the article, said: “Even with a small sample of participants, it was possible to observe a significant difference in the response to chemotherapy. In addition, the dosage used in the research — 2,000 IU per day — is far below the target dose for correcting vitamin D deficiency, which is usually 50,000 IU per week.”
That contrast is significant. Standard clinical vitamin D supplementation for deficiency correction runs to doses more than 17 times higher than what was used in this trial. The researchers were not flooding participants with the vitamin — they were administering what amounts to a gentle daily maintenance dose. The fact that this dose produced a measurable difference in chemotherapy response raises a question that the study itself does not yet answer: is this a floor, or is the effect dose-dependent? Would higher doses produce stronger results, or does the benefit plateau? These are questions that only larger follow-on trials can resolve.
The research, supported by FAPESP — Brazil’s São Paulo Research Foundation — suggests that vitamin D may serve as an alternative to other drugs designed to boost chemotherapy response, especially those that are difficult to access. In high-income healthcare systems, oncologists have access to a growing toolkit of adjunct therapies designed to enhance chemotherapy effectiveness. In lower-resource settings, that toolkit is substantially smaller. A vitamin D supplement that costs a few cents a day and is available globally without a prescription represents a fundamentally different category of intervention — one that could be implemented without additional infrastructure or supply chain complexity.
Why Vitamin D May Matter in Cancer Treatment
The biological plausibility for this finding is well established, even if the clinical evidence has until now been limited.
Vitamin D is not simply a nutrient that helps the body absorb calcium. It functions as a hormone, binding to receptors found in almost every tissue type in the body, including breast tissue and immune cells. Laboratory and animal studies have shown for years that vitamin D can influence how cancer cells grow and die — it has been linked to inhibition of cancer cell proliferation, promotion of apoptosis (programmed cell death), and modulation of inflammatory pathways that tumors exploit to survive.
Since vitamin D also supports immune function — and many cancer patients are deficient — researchers believe the combination may amplify the body’s response to treatment. Scientists say this affordable approach deserves much deeper investigation.
Vitamin D deficiency is remarkably common globally, and it is disproportionately prevalent among postmenopausal women — precisely the demographic represented in this study. This raises a further question: was the supplement’s benefit driven by correcting an underlying deficiency that was undermining chemotherapy effectiveness? Or does vitamin D confer a benefit even in patients who are not deficient? The study’s design does not allow for a definitive answer, but it points toward an important stratification question for future research.
The Limits of a Small Trial
The study enrolled 80 participants across two groups of 40 — a sample size that is standard for a phase 2 exploratory clinical trial but too small to support definitive clinical recommendations. The researchers and independent commentators are consistent on this point: these results are hypothesis-generating, not practice-changing on their own.
What they do is establish the justification for a larger, randomized controlled trial with the statistical power to confirm or refute what the São Paulo team observed. They also establish a specific dose — 2,000 IU daily — and a specific patient profile — women over 45 undergoing neoadjuvant chemotherapy for breast cancer — that future trials can target with precision.
The ethical and practical case for running that trial is strong. The intervention is inexpensive, widely available, well-tolerated, and has a well-understood safety profile at this dose level. The potential upside — a meaningfully higher rate of complete response to chemotherapy in one of the world’s most common cancers — is substantial. The downside risk is minimal.
What Comes Next
The study was led by Eduardo Carvalho-Pessoa, the president of the São Paulo Regional Brazilian Society of Mastology, whose team aimed to investigate the impact of vitamin D supplementation on breast cancer treatment outcomes, particularly in conjunction with chemotherapy. The researchers suggest that vitamin D may enhance immune function, a crucial factor in combating cancer.
The research community’s next step is straightforward in design if not in execution: a multicenter, larger-scale randomized controlled trial that can test the finding across different patient populations, tumor subtypes, chemotherapy regimens, and geographic contexts. Given the global burden of breast cancer — it remains the most commonly diagnosed cancer in women worldwide, with approximately 2.3 million new cases annually — the investment required to run that trial is modest relative to its potential impact.
For the 80 women in São Paulo who participated in this study, and for the patients whose oncologists are now watching these results closely, the story is one of a simple, overlooked intervention that may have been sitting in plain sight. Whether it holds up at scale is the question the next chapter of research will answer.
Disclaimer: The information presented in this article is intended for general informational and news reporting purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Readers should not act upon any health-related information in this article without first consulting a qualified healthcare professional. The study referenced involves a small sample size and has not yet been validated through large-scale clinical trials. Results may not be generalizable to all patient populations. World Reporter does not endorse any specific treatment, supplement, or medical intervention. Always seek the guidance of a licensed physician or other qualified health provider with any questions regarding a medical condition.
